Delegated mode remains in effect. Continue this exact reviewer session. Do not edit source or artifacts and do not claim final acceptance.

## Hard boundaries

- Read only the R11 candidate paths authorized by the conference context.
- Do not read other reviewers' reports.
- Do not modify any R11 artifact, source file, test, Trellis file, context, review, or metric.
- Return the complete review in your final response; the runner alone writes the declared output file.

Read these files only:

- `context/ci-phase10-task102-visual-review-r6_conference_context.md`
- `contracts/kangzhe/design_specs/project_profile.md`
- `docs/decisions/0012-pre-delivery-visual-finalization-loop.md`

Re-review R11 as a visually enabled, native-Chinese senior clinical-trial medical manager. Use actual screenshots or live local HTML, not source-code inference alone. This is a narrow but real delivery review, not a page-load check.

Verify these items with exact R11 evidence:

1. A: efficacy values and comparator values are broadly populated; endpoint/timepoint/analysis-population labels are native Chinese; the efficacy-safety matrix includes Amlitelimab when its three dimensions exist; at 1024 width the complete default matrix graphic is readable without horizontal dragging; inspect overview, efficacy, safety, matrix and Amlitelimab product detail.
2. B: baseline and trial-completion pages remain semantically separated; adherence, loss/exit and protocol-deviation pages show the correct metric families, chart-before-table, explicit unpublished states, and no misleading unit mixing; inspect 1024 and 1440 views.
3. C: treatment-arm placebo matching now uses native Chinese product naming, and inclusion/exclusion criteria remain specific enough to compare score, threshold and timepoint by trial; inspect treatment-arms, inclusion-criteria, exclusion-criteria and at least one trial detail.
4. Across A/B/C: identify any user-visible untranslated English product labels or prose, engineering/log vocabulary, numeric distortion, clipping, excessive truncation, horizontal dragging, or visually misleading comparison. Distinguish internationally recognized generic names in parentheses from avoidable English-only or mixed-language presentation.

Return: (1) resolved/partially resolved/unresolved evidence for the items above; (2) any new P0/P1/P2 defect; (3) separate A/B/C verdicts and overall pass/reject recommendation; (4) minimum repair needed. Machine verifier `ok=true` is supporting evidence only.

Runner-managed report path: `runs/conference/ci-phase10-task102-visual-review-r6/named_antigravity_gemini37_r11_followup.md`
